Growing pharma influence may affect regulatory future of combination products
This article was originally published in Clinica
The medtech industry needs to be particularly aware of the impact that the growing trend in the development of drug/device combination products may have on its future as the drug lobby’s influence grows. That is the view of Shayesteh Fürst-Ladani, director of SFL Regulatory Affairs & Scientific Communication, a newly established consultancy based in Switzerland.
You may also be interested in...
Those marketing products covered under the EU’s MDR and IVD Regulations have plenty of reading this month to help them prepare. More details have also emerged about the UK’s regulatory future.
Where are the biggest challenges for notified bodies and manufacturers now there is some experience with the MDR, and can the sector manage the new regulatory requirements successfully?
The European Commission has finally published detailed guidance on the EU IVDR’s classification rules. The IVDR’s completely new classification regime means guidance is urgently needed.